SG10201500597YA - Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome - Google Patents

Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Info

Publication number
SG10201500597YA
SG10201500597YA SG10201500597YA SG10201500597YA SG10201500597YA SG 10201500597Y A SG10201500597Y A SG 10201500597YA SG 10201500597Y A SG10201500597Y A SG 10201500597YA SG 10201500597Y A SG10201500597Y A SG 10201500597YA SG 10201500597Y A SG10201500597Y A SG 10201500597YA
Authority
SG
Singapore
Prior art keywords
dengue
fever
infections
antibody
mediated
Prior art date
Application number
SG10201500597YA
Other languages
English (en)
Inventor
Neil M Bodie
Original Assignee
Trinity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity Therapeutics Inc filed Critical Trinity Therapeutics Inc
Publication of SG10201500597YA publication Critical patent/SG10201500597YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201500597YA 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome SG10201500597YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8194308P 2008-07-18 2008-07-18

Publications (1)

Publication Number Publication Date
SG10201500597YA true SG10201500597YA (en) 2015-04-29

Family

ID=41551029

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201500597YA SG10201500597YA (en) 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Country Status (13)

Country Link
US (1) US8815813B2 (enExample)
EP (1) EP2320924B1 (enExample)
JP (1) JP5806112B2 (enExample)
CN (1) CN102159231B (enExample)
AU (2) AU2009270805B2 (enExample)
BR (1) BRPI0915968B1 (enExample)
CA (1) CA2731218A1 (enExample)
HR (1) HRP20150620T1 (enExample)
IL (1) IL210717A (enExample)
MX (1) MX2011000647A (enExample)
MY (1) MY160699A (enExample)
SG (1) SG10201500597YA (enExample)
WO (1) WO2010009380A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005221187B2 (en) 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
CN102159231B (zh) 2008-07-18 2016-06-15 三一治疗公司 治疗免疫介导的登革热感染和登革热感染(包括登革出血热和登革休克综合征)的抗体依赖性增强作用的方法
US20170360875A1 (en) * 2014-12-22 2017-12-21 Middle Tennessee State University Methods for treating immune-mediated viral infections
JP6872181B2 (ja) * 2015-05-20 2021-05-19 国立大学法人 鹿児島大学 IgG結合ペプチドによる抗体の特異的修飾
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
CN115804362A (zh) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4383317A (en) 1980-10-30 1983-05-10 Bei Electronics, Inc. Shaft angle encoder having a circuit for synthesizing a skipped track output signal
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5693758A (en) 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US5932483A (en) 1990-10-16 1999-08-03 Northwestern University Synthetic peptide and its uses
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
ITMI962628A1 (it) 1996-12-16 1998-06-16 Tecnogen Scpa Composizione farmaceutica
CN1189166C (zh) 1998-09-11 2005-02-16 伊来克萨斯独资有限公司 Fc受体调节剂及其应用
JP2002534059A (ja) 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション,インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1332158B1 (de) 2000-11-08 2007-08-01 Fresenius Medical Care Affina GmbH Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
DE60318065T2 (de) 2002-06-07 2008-11-20 Trillium Therapeutics Inc., Toronto Fcyriia-transgenes tiermodell für autoimmunkrankheit
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
AU2005221187B2 (en) * 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
AU2005272598B2 (en) 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US20080187490A1 (en) 2005-09-06 2008-08-07 Bodie Neil M Methods for Treating Amyotrophic Lateral Sclerosis
ES2359218T3 (es) 2005-12-13 2011-05-19 Suppremol Gmbh POLIPÉPTIDOS Y POLIMÉRICOS PARA LOS RECEPTORES Fc.
US20120021988A1 (en) 2007-08-14 2012-01-26 Bodie Neil M Methods for treating immune thrombocytopenia
CN102159231B (zh) 2008-07-18 2016-06-15 三一治疗公司 治疗免疫介导的登革热感染和登革热感染(包括登革出血热和登革休克综合征)的抗体依赖性增强作用的方法

Also Published As

Publication number Publication date
IL210717A0 (en) 2011-03-31
CN102159231A (zh) 2011-08-17
IL210717A (en) 2017-07-31
US8815813B2 (en) 2014-08-26
BRPI0915968B1 (pt) 2021-11-23
WO2010009380A9 (en) 2010-04-08
JP2011528665A (ja) 2011-11-24
HRP20150620T1 (xx) 2015-09-25
HK1158066A1 (en) 2012-07-13
JP5806112B2 (ja) 2015-11-10
US20110218157A1 (en) 2011-09-08
EP2320924A4 (en) 2012-07-25
WO2010009380A2 (en) 2010-01-21
MX2011000647A (es) 2011-09-29
CA2731218A1 (en) 2010-01-21
AU2017200760A1 (en) 2017-03-02
EP2320924B1 (en) 2015-03-11
MY160699A (en) 2017-03-15
EP2320924A1 (en) 2011-05-18
AU2009270805B2 (en) 2016-11-03
CN102159231B (zh) 2016-06-15
BRPI0915968A2 (pt) 2020-08-18
AU2009270805A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
GB2471806B (en) Compositions and methods for treating viral infections
LT2083811T (lt) Dauno sindromo, trapiosios x chromosomos sindromo ir autizmo gydymo būdai
IL210717A0 (en) Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
EP2124921A4 (en) SULFONYL SEMI-CARBAZIDES, CARBONYL SEMI-CARBAZIDS, SEMI-CARBAZIDS AND UREA, PHARMACEUTICAL COMPOSITIONS THEREOF, AND PROCESS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING ARENAVIRUS-ASSOCIATED INFECTIONS
IL185056A0 (en) Compositions and methods for treating or preventing flaviviridae infections
EP2344155A4 (en) COMPOSITION AND METHOD FOR TREATING A DRY EYE
ZA200904492B (en) Compositions and methods for the treatment of infections and tumors
ZA201005737B (en) Methods of treating viral infections
PT1951633T (pt) Composição para vidro de elevado desempenho, fibras de vidro de elevado desempenho e artigos feitos a partir das mesmas
WO2011056650A9 (en) Methods and compositions for treating and preventing viral infections
ZA200905990B (en) Recombinant antibodies for treatment of respriratory syncytial virus infections
IL209380A0 (en) Small molecule inhibitors for the treatment or prevention of dengue virus infection
BRPI0820139A2 (pt) Composição antiperspirante ativa, e, processo de obtenção de uma composição antiperspirante ativa
IL195272A0 (en) Methods and compositions for the treatment of viral infections
EP2060949A4 (en) RADIATION-SENSITIVE COMPOSITION AND PROCESS FOR PRODUCING A LOW-MOLECULAR COMPOUND FOR USE THEREIN
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
DK2158281T3 (da) Farvepigmenteret laksammensætning med høj dækkeevne, forøget ridsefasthed, og let-at-rengøre egenskaber
BRPI0920892A2 (pt) Composição de bebida e processo de redução de degradação de monatina.
IL210682A0 (en) Glass hardening methods and compositions
ZA201100779B (en) Composition for reinforcing hollow glass and protecting same from scratching,corresponding treatment methods and resulting treated hollow glass
EP1937235A4 (en) METHOD FOR TREATING VIRUS INFECTIONS WITH POLYAMINE ANALOGUE
EP2086560A4 (en) METHODS OF TREATING EPIPHORA
ZA200904068B (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
IL199113A0 (en) Compositions and methods for treating infectious bronchitis
IL196825A0 (en) Methods, compositions and articles of manufacture for contributing to the treatment of cancers